Yanbin Yao

Yanbin Yao


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2025 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
MXMing Xie
Ming Xie
NZNian Zhou
Nian Zhou
QLQian Liang
Qian Liang
ZLZhong Lin
Zhong Lin
YYYanbin Yao
Yanbin Yao
Background IgA vasculitis (IgAV) is an autoimmune disorder characterized by inflammation of the small blood vessels. The pathogenesis of IgAV is believed to involve a complex interplay between immune cells, metabolites, and inflammatory cytokines (ICs). Methods We performed two-sample Mendelian randomization (MR) analysis to examine the causal relationship between immune cell traits, metabolites, ICs, and IgAV. Genetic variants associated with exposure, mediators and outcome were extracted from large-scale genome-wide association studies (GWAS). The inverse variance weighted (IVW) method was used as the primary approach, supported by MR Egger, weighted median, simple mode, and weighted mode methods. Results In this study, we identified 25 immune cells, 6 metabolites (Threonate, Carnitine C5:1, Chiro-inositol, Carnitine C18:2, 3-formylindole, Cholate to phosphate ratio) and 2 ICs (T − cell surface glycoprotein CD5, Osteoprotegerin) associated with IgAV. Meanwhile, we identified 5 immune cell—metabolites—IgAV pathways (CD28+CD45RA−CD8dim AC—3-formylindole—IgAV; CD28+ CD45RA− CD8dim AC—Cholate to phosphate ratio—IgAV; CD28+ CD45RA+ CD8br%T cell—3-formylindole—IgAV; CD25 on IgD+ CD38− unswmem—Chiro-inositol- IgAV; HLA DR on CD14+ CD16− monocyte—Chiro-inositol—IgAV; CD39+ secreting Treg %secreting Treg-Threonate—IgAV) and 4 immune cells—ICs—IgAV pathways (IgD− CD38− AC—Osteoprotegerin—IgAV; CD45 on T—Osteoprotegerin—IgAV; HLA DR on CD14+ CD16− monocyte—CD5—IgAV; HLA DR on CD14+CD16− monocyte—CD5—IgAV). Conclusions These results highlight the need for further research to investigate the underlying mechanisms and identify potential therapeutic targets for the treatment of IgAV.

8 May 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WWWenqiang Wang
Wenqiang Wang
XPXiao Peng
Xiao Peng
QHQikai Hua
Qikai Hua
YYYanbin Yao
Yanbin Yao
Diabetic foot ulcer (DFU) is a severe diabetes complication affecting 15–25% of patients and frequently causing lower extremity amputations. While ubiquitination regulates diverse cellular functions, ubiquitination-related genes (URGs) in DFU pathogenesis remain unexplored. We analyzed single-cell RNA sequencing data from 29 samples (19 controls, 10 DFU) and bulk RNA sequencing from 60 samples (25 controls, 35 DFU). Using 1,610 URGs from GeneCards database, we performed single-cell analysis, pseudotime analysis, and cell communication studies. Four machine learning algorithms identified diagnostic biomarkers, followed by functional enrichment, immune infiltration, and molecular docking analyses. Key gene expression patterns were further validated by quantitative real-time PCR (qPCR) in independent clinical samples (n = 6 per group). Single-cell analysis identified 12 cell types with significantly elevated URGs in DFU fibroblasts. A pathogenic fibroblast subpopulation exhibited enhanced stemness and dysregulated communication networks. Machine learning identified four key URGs (MEF2A, SKIL, MAF, KRT5) as diagnostic biomarkers, achieving optimal performance (AUC 0.957). SKIL showed strongest correlation with metabolic reprogramming. Two distinct molecular subtypes with different immune profiles were identified. Lumicolchicine and ramipril were identified as potential SKIL-targeting therapeutics. This study provides the first URGs characterization in DFU, identifying pathogenic fibroblasts and SKIL as key regulators. The diagnostic signature and therapeutic targets establish foundations for precision DFU treatment approaches. These findings support the development of URG-based diagnostic strategies and provide a translational rationale for repurposing clinically approved drugs, such as ramipril, for precision management of DFU.